In Practice Systems Limited

Codex IT Acquires Computer Infrastructure Support Company

Retrieved on: 
Mardi, avril 4, 2023
In Practice Systems Limited, Organization, City, Member of the Scottish Parliament, Acquisition, Patient, Codex, Retail

COLUMBUS, Ohio, April 4, 2023 /PRNewswire/ -- Codex IT, a national leader in healthcare technology solutions and managed services, just announced the acquisition of Practical Systems, LLC, a computer infrastructure support company based in Cayce, South Carolina, outside of Columbia. Codex IT CEO, Wes Strickling & Practical Systems owners Kevin Lawson and Greg Larson worked to bring the two organizations together.

Key Points: 
  • COLUMBUS, Ohio, April 4, 2023 /PRNewswire/ -- Codex IT, a national leader in healthcare technology solutions and managed services, just announced the acquisition of Practical Systems, LLC, a computer infrastructure support company based in Cayce, South Carolina, outside of Columbia.
  • Codex IT CEO, Wes Strickling & Practical Systems owners Kevin Lawson and Greg Larson worked to bring the two organizations together.
  • This acquisition allows Codex IT to continue to expand its national footprint to six support centers across the U.S. as one of the leading healthcare-focused MSPs.
  • "We are excited about partnering with Codex IT to increase our capacity and to exceed our clients' technology support expectations.

EQS-News: VisionHealth raises 3 million Euro to finance extended COPD and asthma study for market preparation of Kata®, an innovative digital therapeutic for improved inhalation

Retrieved on: 
Lundi, février 27, 2023
Clinical trial, Chronic Respiratory Disease, Single-frequency network, Contract research organization, Life, Respiratory failure, DuPont, Business, MDR, Patient, Chronic obstructive pulmonary disease, Estonia, Hoechst, Growth, Medical device, Therapy, Medical Devices Directive, In Practice Systems Limited, Inhalation, Business development, Asthma, Chronic lung disease, Friends, Hospital, MDD, CE, Physician, Lung, Security (finance), Pharmaceutical industry, COPD, EU

He will take a seat on the non-executive Board of VisionHealth.

Key Points: 
  • He will take a seat on the non-executive Board of VisionHealth.
  • The study is designed as a randomly controlled, multi-centric trial over the period of one year with around 120 patients suffering from chronic respiratory diseases such as asthma or COPD.
  • It is truly rewarding to see how we can make a difference for patients and improve health outcomes.
  • Worldwide, Kata® could support the therapy of approximately 250 million patients suffering from chronic respiratory diseases, with an estimated 8.9 million cases alone in Germany.8,9

Association for Computing Machinery Awards Raluca Ada Popa, President and Founder of Opaque Systems and UC Berkeley PhD, the 2021 Grace Murray Hopper Award

Retrieved on: 
Mardi, juillet 26, 2022
Running, Ant Group, University of California, Berkeley, MC2, University, MIT, Intelligence, Confidentiality, Computer science, AMC, Doctor of Philosophy, Electrical engineering, Research, MIT Department of Brain and Cognitive Sciences, Scotiabank, Engineering, Grace Murray Hopper Award, UC, Ericsson, In Practice Systems Limited, Organization, Leadership, Machine learning, Technology, TEE, Analytics, AI, ACM, IBM, Cryptocurrency

BERKELEY, Calif. , July 26, 2022 /PRNewswire/ -- Opaque Systems, the company pioneering Confidential AI and Analytics which enables collaborative analytics and AI for confidential computing, today announced its president and co-founder Raluca Ada Popa, MS, PhD, is the recipient of the 2021 AMC Grace Murray Hopper Award. Raluca Ada Popa is recognized for her exceptional impact and contributions to building secure systems focused on protecting the confidentiality of data stored on remote servers including recent open sourced innovation MC2.

Key Points: 
  • The ACM Grace Murray Hopper Award is given to outstanding computer professionals selected on the basis of a single recent major technical or service contribution.
  • This prestigious honor comes at a time when confidential computing is experiencing increasing market demand across Global 2000 organizations.
  • Popa is accelerating innovation with her company, Opaque Systems, that raised its $22M Series A funding in June.
  • "I am delighted to receive the 2021 ACM Grace Murray Hopper award," said Popa.

DGAP-News: VisionHealth and Boehringer Ingelheim: Digital therapy support for asthma and COPD

Retrieved on: 
Mardi, juillet 12, 2022
Knowledge, Feedback, Artificial intelligence, Degenerative disease, Chronic Respiratory Disease, Boehringer Ingelheim, COPD, Inhalation, Certification, Patient, CEO, Physician, Chronic lung disease, Animal Health, IIA, HIV disease progression rates, Asthma, Intelligence, In Practice Systems Limited, Industry, Chronic obstructive pulmonary disease, Medical device, Fine chemical

Munich, July 12th, 2022 VisionHealth and Boehringer Ingelheim will cooperate on the Kata app for therapy support in asthma and chronic obstructive pulmonary disease (COPD).

Key Points: 
  • Munich, July 12th, 2022 VisionHealth and Boehringer Ingelheim will cooperate on the Kata app for therapy support in asthma and chronic obstructive pulmonary disease (COPD).
  • The Kata app is a certified Class IIa medical device that provides targeted inhalation support for people with chronic respiratory diseases.
  • VisionHealth developed the Kata app with the aim of guiding the inhalation process for patients suffering from chronic respiratory diseases such as asthma or COPD.
  • Kata is a VisionHealth proprietary platform based on artificial intelligence to support inhalation therapy.

DGAP-News: VisionHealth's Kata Clinical to be included into Alcedis service platform for clinical studies

Retrieved on: 
Mardi, février 1, 2022
CEO, Inhalation, Degenerative disease, Patient, Feedback, Automation, Lung, Artificial intelligence, Clinical trial, GCP, Trial of the century, Physician, Probability, Chronic lung disease, Technology, Intelligence, Research, Asthma, COPD, Certification, Data collection, Science, Knowledge, Single-frequency network, In Practice Systems Limited, CRO, Industry, Chronic obstructive pulmonary disease, Medical device, Pharmaceutical industry, VisionHealth, Kata(R), VISIONHEALTH, KATA(R)

"We are delighted to win Alcedis as a strong partner for data-driven clinical trials in respiratory diseases.

Key Points: 
  • "We are delighted to win Alcedis as a strong partner for data-driven clinical trials in respiratory diseases.
  • The technology of Alcedis service platform brings together science, technology and innovation to offer customized concepts for highly qualitative studies," said Dr. Sabine Huermann, CEO and founder of VisionHealth GmbH.
  • Therefore, we are excited to work with VisionHealth and be able to include Kata(R) Clinical into our service platform," Hanno Hrtlein, Managing Director of Alcedis, commented.
  • Kata(R) Clinical complies with the criteria of good clinical praxis (GCP) and meets all technical, regulatory and data protection regulations, qualifying it for the use in clinical studies.

DGAP-News: VisionHealth receives EU Medical Device Regulation certification

Retrieved on: 
Lundi, décembre 20, 2021
Chronic Respiratory Disease, Certification, Company, Medical Devices Directive, IIA, Asthma, Physician, Intelligence, Feedback, Industry, Degenerative disease, Chronic lung disease, Medical device, Lung, CEO, Inhalation, Hospital, Single-frequency network, Patient, Artificial intelligence, Regulation, Knowledge, CE, DiGa, Data collection, EN, MDR, Chronic obstructive pulmonary disease, MDD, In Practice Systems Limited, Compliance, Automation, COPD, VisionHealth, Kata(R), VISIONHEALTH, KATA(R)

MDR certification prerequisite to enhance, further develop and release future Kata(R) versions

Key Points: 
  • MDR certification prerequisite to enhance, further develop and release future Kata(R) versions
    Munich (Germany), December 20, 2021 - VisionHealth GmbH, a pioneer in digital therapeutics (DTx) for the inhaled treatment of chronic lung diseases, today announced the successful certification of its quality management system according to the new EU Medical Device Regulation (MDR 2017/745) and EN ISO 13485.
  • With the regulatory change from the Medical Device Directive (MDD) to MDR, requirements for both manufacturers and notified bodies have changed significantly.
  • This certification allows us to advance our platform to further strengthen the benefits patients and medical professionals can take from Kata(R).
  • Certification also proves that VisionHealth is a reliable partner and represents an important milestone on our path towards DiGA application," said Dr. Sabine Huermann, CEO and founder of VisionHealth GmbH.

DGAP-News: sterna biologicals announces dosing of first patient in phase IIa proof-of-concept study with SB010 in moderate to severe asthma

Retrieved on: 
Lundi, décembre 20, 2021
Nitric acid, Hope, Global Initiative, Company, IIA, Hospital, Epigenetics of diabetes Type 2, LABA, The New England Journal of Medicine, Sterna, POC, Today, Pulmonology, Pharmacokinetics, Clinic, ICS, Inhalation, Safety, Inflammation, Patient, Global Initiative for Asthma, Ulcerative colitis, Hannover Medical School, Factor X, GINA, COPD, Bronchospasm, Atopic dermatitis, Immunomodulation, Chronic obstructive pulmonary disease, In Practice Systems Limited, Asthma, Deoxyribozyme, Gesellschaft mit beschränkter Haftung, Aquaculture, Pharmaceutical industry

"We are pleased that the first patient has been treated in our GIANT-1 trial with inhaled SB010 in patients with uncontrolled moderate to severe asthma," said Dr. Marion Wencker, Chief Medical Officer of sterna biologicals.

Key Points: 
  • "We are pleased that the first patient has been treated in our GIANT-1 trial with inhaled SB010 in patients with uncontrolled moderate to severe asthma," said Dr. Marion Wencker, Chief Medical Officer of sterna biologicals.
  • "I am excited about the potential SB010 holds in treating patients with moderate to severe uncontrolled asthma.
  • In this study, sterna will for the first time, combine pharmacological and digital therapy by integrating VisionHealth's Kata(R) Clinical into the trial.
  • Consequently, the Company's therapeutic candidates containing hgd40, SB010 and SB012, address several inflammatory processes simultaneously and rebalance an overall dysregulated immune response.

DGAP-News: VisionHealth's Kata(R) Clinical app to support sterna biologicals' clinical Phase IIa asthma trial

Retrieved on: 
Mardi, novembre 23, 2021
Patient, Gesellschaft mit beschränkter Haftung, COPD, Trial of the century, Chronic obstructive pulmonary disease, Automation, Safety, CEO, Clinical trial, Technology, Industry, Data management, Data collection, Asthma, Company, POC, Single-frequency network, Deoxyribozyme, Contract research organization, Inhalation, Factor X, Form 1099, Physician, App, Atopic dermatitis, CRO, Ulcerative colitis, Artificial intelligence, Collection, Certification, Knowledge, Sterna, Chronic lung disease, Degenerative disease, Disease, Intelligence, In Practice Systems Limited, Pharmaceutical industry, Medical device, VisionHealth, Kata(R), sterna biologicals, VISIONHEALTH, KATA(R), STERNA BIOLOGICALS

Kottmann GmbH & Co. KG, a Clinical Research Organization (CRO) that will apply Kata(R) Clinical also beyond this trial.

Key Points: 
  • Kottmann GmbH & Co. KG, a Clinical Research Organization (CRO) that will apply Kata(R) Clinical also beyond this trial.
  • Kata(R) Clinical is a modified Kata(R) app for Clinical Trials from VisionHealth's artificial intelligence proprietary platform for inhalation therapy support.
  • The App is offered to pharma, biotech and CRO partners to support clinical trials in the respiratory field.
  • For sterna's asthma trial, VisionHealth adapted Kata(R) Clinical to specifically support the run-in period for patient preparation and therapy adherence, ensuring the correctly performed inhalation with SB010.

DGAP-News: sterna biologicals GmbH & Co. KG: STERNA BIOLOGICALS RECEIVES APPROVAL FOR INNOVATIVE PHASE II A STUDY DESIGN IN ASTHMA COMBINING A NOVEL ANTISENSE-BASED TREATMENT WITH A DIGITAL THERAPY

Retrieved on: 
Mardi, novembre 23, 2021
Patient, Gesellschaft mit beschränkter Haftung, COPD, Safety, Inflammation, Company, Asthma, POC, IIA, Deoxyribozyme, Inhalation, Factor X, The New England Journal of Medicine, Atopic dermatitis, Chronic obstructive pulmonary disease, DIGITAL, Ulcerative colitis, Artificial intelligence, Medical device, ICS, Sterna, Chronic lung disease, LABA, CTA, Degenerative disease, Immunomodulation, Mark (given name), In Practice Systems Limited, Aquaculture, Pharmaceutical industry

DGAP-News: sterna biologicals GmbH & Co. KG

Key Points: 
  • DGAP-News: sterna biologicals GmbH & Co. KG
    sterna biologicals GmbH & Co. KG: STERNA BIOLOGICALS RECEIVES APPROVAL FOR INNOVATIVE PHASE II A STUDY DESIGN IN ASTHMA COMBINING A NOVEL ANTISENSE-BASED TREATMENT WITH A DIGITAL THERAPY
    The issuer is solely responsible for the content of this announcement.
  • -Phase IIa proof-of-concept (POC) study with novel catalytic antisense oligonucleotide SB010 in patients with moderate to severe asthma initiated.
  • The combination of these functions specifically tailored to the study design will ensure optimal data reliability and meaningfulness.
  • The company develops innovative and unique digital health solutions enabling sustainable improvements in existing standard therapy for patients with chronic lung diseases like asthma and COPD.

DGAP-News: VisionHealth adds Clinical Trial Function to Kata App supporting and optimizing inhalation therapy of chronic lung diseases

Retrieved on: 
Jeudi, novembre 4, 2021
Inhalation, Chronic obstructive pulmonary disease, Cros, Industry, Knowledge, Certification, Form 1099, Data collection, Patient, Data management, Machine learning, Single-frequency network, In Practice Systems Limited, GCP, Degenerative disease, Review, Chronic Respiratory Disease, Intelligence, Collection, Clinical trial, CEO, Chronic lung disease, Artificial intelligence, Hospital, Asthma, HIV disease progression rates, Automation, Physician, Medical device, VisionHealth, Kata, VISIONHEALTH, KATA

The newly launched Kata(R) Clinical allows remote collection of high-quality data, including clinical parameters and conditions.

Key Points: 
  • The newly launched Kata(R) Clinical allows remote collection of high-quality data, including clinical parameters and conditions.
  • The Kata(R) platform builds on VisionHealth's proprietary artificial intelligence (AI) algorithm to monitor and support correct inhalator usage for the therapy of chronic lung diseases.
  • The aim of the Kata(R) app for patients is to optimize the drug inhalation therapy of chronic lung diseases through digital support.
  • A modified Kata(R) app for Clinical Trials (Kata(R) Clinical) combines data and patient management to enhance the participants' experience and improve study outcomes at the same time.